Weshalb die Actinium Pharmaceuticals-Aktie
ein D-Rating hat,
erfahren Sie im Performance-Check
vom 17. September 2025 Info.
Rang | Datum | Vorjahr | Schluss | Performance |
---|---|---|---|---|
1 | 2022 | 5,30 | 9,63 | 81,70% |
2 | 2020 | 5,30 | 6,75 | 27,36% |
3 | 2025 | 1,16 | 1,39 | 19,83% |
4 | 2021 | 6,75 | 5,30 | -21,48% |
5 | 2019 | 7,83 | 5,30 | -32,31% |
6 | 2017 | 25,23 | 16,59 | -34,24% |
7 | 2015 | 155,31 | 84,00 | -45,91% |
8 | 2018 | 16,59 | 7,83 | -52,80% |
9 | 2023 | 9,63 | 4,46 | -53,69% |
10 | 2016 | 84,00 | 25,23 | -69,96% |
11 | 2024 | 4,46 | 1,16 | -73,99% |
Rang | Datum | Vorjahr | Schluss | Performance |
---|---|---|---|---|
1 | 2024 | 4,46 | 1,16 | -73,99% |
2 | 2016 | 84,00 | 25,23 | -69,96% |
3 | 2023 | 9,63 | 4,46 | -53,69% |
4 | 2018 | 16,59 | 7,83 | -52,80% |
5 | 2015 | 155,31 | 84,00 | -45,91% |
6 | 2017 | 25,23 | 16,59 | -34,24% |
7 | 2019 | 7,83 | 5,30 | -32,31% |
8 | 2021 | 6,75 | 5,30 | -21,48% |
9 | 2025 | 1,16 | 1,39 | 19,83% |
10 | 2020 | 5,30 | 6,75 | 27,36% |
11 | 2022 | 5,30 | 9,63 | 81,70% |